|6.27||-0.2800||-4.27%||Vol 646.19K||1Y Perf -70.91%|
|Jun 28th, 2022 16:00 DELAYED|
|- -||0.31 4.94%|
|Target Price||11.22||Analyst Rating||Hold 2.79|
|Potential %||78.95||Finscreener Ranking||★ 40.01|
|Insiders Trans % 3/6/12 mo.||-50/-67/-67||Value Ranking||★+ 43.76|
|Insiders Value % 3/6/12 mo.||6/-4/-4||Growth Ranking||★+ 41.85|
|Insiders Shares Cnt. % 3/6/12 mo.||0/-10/-10||Income Ranking||— -|
|Price Range Ratio 52W %||14.61||Earnings Rating||Sell|
|Market Cap||395.05M||Earnings Date||2nd Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd Aug 2022|
|Estimated EPS Next Report||-0.95|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||932.10K|
|Avg. Monthly Volume||881.21K|
|Avg. Quarterly Volume||1.20M|
Esperion Therapeutics Inc. (NASDAQ: ESPR) stock closed at 6.55 per share at the end of the most recent trading day (a 1.24% change compared to the prior day closing price) with a volume of 683.99K shares and market capitalization of 395.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 479 people. Esperion Therapeutics Inc. CEO is Timothy M. Mayleben.
The one-year performance of Esperion Therapeutics Inc. stock is -70.91%, while year-to-date (YTD) performance is 31%. ESPR stock has a five-year performance of -86.43%. Its 52-week range is between 3.28 and 23.75, which gives ESPR stock a 52-week price range ratio of 14.61%
Esperion Therapeutics Inc. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 80.52, a price-to-sale (PS) ratio of 4.62, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -77.53%, a ROC of -194.99% and a ROE of 93.32%. The company’s profit margin is -66.86%, its EBITDA margin is -203.80%, and its revenue ttm is $89.31 Million , which makes it $1.42 revenue per share.
Of the last four earnings reports from Esperion Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.95 for the next earnings report. Esperion Therapeutics Inc.’s next earnings report date is 02nd Aug 2022.
The consensus rating of Wall Street analysts for Esperion Therapeutics Inc. is Hold (2.79), with a target price of $11.22, which is +78.95% compared to the current price. The earnings rating for Esperion Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Esperion Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Esperion Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.79, ATR14 : 0.42, CCI20 : 167.60, Chaikin Money Flow : 0.15, MACD : 0.13, Money Flow Index : 69.03, ROC : 7.38, RSI : 61.50, STOCH (14,3) : 95.53, STOCH RSI : 1.00, UO : 61.57, Williams %R : -4.47), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Esperion Therapeutics Inc. in the last 12-months were: Eric Warren (Sold 452 shares of value $2 427 ), J. Martin Carroll (Buy at a value of $28 180), Sheldon L. Koenig (Sold 5 694 shares of value $27 949 )
Tue, 03 May 2022 15:55 GMT Esperion (ESPR) Receives a Buy from JMP Securities- TipRanks. All rights reserved.
Mon, 25 Apr 2022 16:05 GMT Esperion (ESPR) Receives a Buy from H.C. Wainwright- TipRanks. All rights reserved.
Tue, 11 Jan 2022 22:25 GMT Esperion (ESPR) Gets a Buy Rating from Needham- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.